T-Systems is now our official partner in Switzerland and is offering Prostate.Carcinoma.ai as on-premise solution
Photo: The T-Systems Switzerland team with Matthias Steffen
Have a look at the press release here:
T-Systems distributes AI-based Radiology Software from FUSE-AI
Radiology clinics and practices in Switzerland can now obtain the AI-based software "Prostate.Carcinoma.ai" from the Hamburg-based e-health company FUSE-AI centrally through T-Systems, which assists radiologists in analyzing prostate MR images. The two companies have signed a corresponding cooperation agreement. Healthcare facilities benefit from the industry and technology know-how of two experienced players.
"Prostate.Carcinoma.ai" has been certified as a Class IIa medical device in Europe, and thus also in Switzerland, by the certification body BSI Group since December 2023. The software seamlessly integrates as a plug-in into existing PACS systems. "This makes the application particularly user-friendly. It enables radiologists to analyze and process a tremendous volume of images in the shortest possible time," explains Peter Nikles, Head of Vertical Healthcare & Public at T-Systems Switzerland. "The time savings of about 30 percent per patient lead to increased efficiency and considerable financial benefits for clinics and practices." The software is available on T-Systems' Swiss Open Telekom Cloud, a community cloud exclusively tailored to the special security and data protection requirements of the Swiss market, or as an on-premise solution.
The solution was trained based on annotations by experienced radiologists and pathohistological data. Only when both sources identified abnormalities were the MRI images used to train the algorithm. This method significantly increases the detection rate of the software compared to the evaluation of images by the human eye.
"Artificial intelligence will gain increasing importance in all sectors where data-driven processes play a role over the next few years. Shortages of skilled workers, efficiency gains, and revenue growth are the drivers in this technological paradigm shift, which affects not only medicine," says Matthias Steffen, co-founder and CEO of FUSE-AI.
"Prostate.Carcinoma.ai" is just the starting point for the development of a whole series of AI-supported diagnostic assistant software solutions for different medical indications. Further use cases are in planning. The solution will be presented at the Future Arena on September 9, 2024, at the Wankdorf Stadium in Bern.